NCT03239756UnknownPhase 1
Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases
Jiangsu T-Mab Biopharma Co.,Ltd1 site in 1 country40 target enrollmentStarted: July 20, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Frequency of adverse events (AEs) and serious adverse events (SAEs) which are related to TK006 assessed by CTCAE v4.03
Study Overview
Brief Summary
This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases.
Detailed Description
This is an single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple subcutaneous injection TK006 in patients with breast cancer-related bone metastases. It contains 4 cohorts：60 mg single-dose conhort, 120 mg single-dose conhort, 180 mg single-dose conhort and 120 mg Q4W （one dose every 4 weeks, 3 dose totally） conhort.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients provide written informed consent voluntarily；
- •18~65 years old；
- •Patients with pathology confirmed breast cancer radiological evidence with bone metastasis；
- •Eastern Cooperative Oncology Group(ECOG) performance status≤2
- •Anticipated life span≥6-month；
- •Adequate reservation of hematopoiesis, liver and kidney functions:
- •Absolute neutrophil count (ANC) ≥1.5×10^9/L
- •Absolute platelet count (PLT) ≥100×10^9/L
- •Hemoglobin (Hb) ≥90 g/L
- •Total bilirubin (TBIL) ≤1.0 time the upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0 ULN
- •Serum creatinine (sCr) ≤2.0 ULN
- •Albumin-adjusted calcium≥2.0 mmol/L, ≤2.9 mmol/ L(Calcium supplements are not allowed within 8 hours before examination).
Exclusion Criteria
- •Hypersensitivity to any investigational medicine or supplements in this study.
- •Women in Pregnancy or nursing.
- •Anti-human immunodeficiency virus (HIV) antibody positive.
- •Patients with hepatitis B virus DNA ≥10^5 copies/mL or active hepatitis C would not be selected. Stable hepatitis B or hepatitis C defined as AST/ALT≤2 ULN will not be selected as well if patients are not treated with antiviral therapy while receving immunosuppressive therapy or chemotherapy meanwhile.
- •Prior malignancies (excluding the targeted breast cancer, basal cell carcinoma, or cervical cancer in situ) within 3 years.
- •Uncontrolled systemic diseases, or organic or mental disorders that could affect compliance.
- •Central nervous system metastasis that is symptomatic or require treatment.
- •Unresolved toxicities ≥2 grades from previous chemo-therapy (excluding alopecia).
- •Major surgery of bone or trauma within 4 weeks before the first dosing.
- •Fracture of long bone within 90-day before the first dosing.
- •Radiation therapy to bone within 2 weeks or treatment with radioisotopes within 8 weeks before the first dosing.
- •Treatment with diphosphonate within 30-day or administration of calcitonin, parathyroid hormone-related peptides, mithramycin, gallium nitrate or strontium ranelate within 6-month before the first dosing. Plan to receive systemic treatment with glucocorticosteroids over a long period during the trial.
- •Hyperthyroidism or hypothyroidism, unless hypothyroidism patients are receiving regular treatment with thyroid hormone and:
- •1) Thyroid stimulating hormone (TSH) is normal, or 2) TSH>4.78μIU/Ml, ≤10.0μIU/mL and thyroxine (T4) is normal.
- •Disorders of hypoparathyroidism or hyperparathyroidism, osteomalacia, rheumatoid arthritis, acute attack of osteoarthritis, gout, Paget's disease, malabsorption syndrome, ascites, or other diseases that could affect bone metabolism.
- •15. Previous or existing osteomyelitis or osteonecrosis of jaw, odontia or jaw diseases which are in active or require invasive operations, unhealing wound of oral surgery, or planned invasive dental operations during this trial.
- •16. Has been selected for the study of other test devices or test drugs, or the duration of the clinical studies that have taken less than 30 days or 5 half-lives or biological effects, whichever is longer.
- •17. Other situations which are not suitable for participation judged by the principal investigator (PI).
Outcomes
Primary Outcomes
Frequency of adverse events (AEs) and serious adverse events (SAEs) which are related to TK006 assessed by CTCAE v4.03
Time Frame: single dose cohort：112 days, multiple dose cohort：140 days
Collect the information of AEs and SAEs, vital sign, physical examination, laboratory examination and electrocardiogram during the trial.
Secondary Outcomes
- bioavailability corrected apparent volume of distribution [Vd/F](single dose cohort：112 days, multiple dose cohort：140 days)
- Maximum observed maximum plasma concentration [Cmax](single dose cohort：112 days, multiple dose cohort：140 days)
- Time to reach the maximum observed plasma concentration [Tmax](single dose cohort：112 days, multiple dose cohort：140 days)
- Area under the plasma concentration-time curve from time zero to time 'last' where last is the last time point after administration [AUClast](single dose cohort：112 days, multiple dose cohort：140 days)
- Area under the plasma concentration-time curve from time zero to infinity [AUC0-inf](single dose cohort：112 days, multiple dose cohort：140 days)
- Terminal elimination half-life[T1/2](single dose cohort：112 days, multiple dose cohort：140 days)
- bioavailability corrected apparent volume of the central compartment cleared of drug per unit [Cl/F](single dose cohort：112 days, multiple dose cohort：140 days)
- urine creatinine corrected cross-linked N-telopeptides of type I collagen [uNTX/Cr](single dose cohort：112 days, multiple dose cohort：140 days)
- serum bone alkaline phosphatase [bALP](single dose cohort：112 days, multiple dose cohort：140 days)
- anti-drug antibody [ADA](single dose cohort：112 days, multiple dose cohort：140 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple MyelomaMultiple MyelomaNCT01025206BioInvent International AB35
Completed
Phase 1
Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsHIV InfectionsNCT03735849National Institute of Allergy and Infectious Diseases (NIAID)28
Completed
Phase 2
CP-675,206 In Patients With Advanced MelanomaMalignant MelanomaNCT00086489AstraZeneca118
Completed
Phase 1
Study of the CD40 Agonistic Monoclonal Antibody APX005MUrothelial CarcinomaMSI-HHead and Neck CancerCancerMelanomaNSCLCNCT02482168Apexigen America, Inc.43
Terminated
Phase 1
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UKPlasmodium FalciparumMalariaNCT05400746University of Oxford17